Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 6
Submit an article Journal homepage
244
Views
32
CrossRef citations to date
0
Altmetric
Review

Factors of importance for a successful delivery system for proteins

Marco van de Weert The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, 2100 Copenhagen, Denmark. [email protected]
,
Lene Jorgensen The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, 2100 Copenhagen, Denmark. [email protected]
,
Eva Horn Moeller The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, 2100 Copenhagen, Denmark. [email protected]
&
Sven Frokjaer The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, 2100 Copenhagen, Denmark. [email protected]
Pages 1029-1037 | Published online: 04 Nov 2005

Bibliography

  • WALSH G: Pharmaceutical biotechnology products approved within the European Union. Eur. j Pharm. Biopharm. (2003) 55:3–10.
  • WALSH G: Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol (2005) (In press).
  • CROMMELIN DJ, STORM G, VERRIJK R, LEEDE L, JISKOOT W, HENNINK WE: Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. mt. Pharm. (2003) 266:3–16.
  • •Gives a good comparison of the difference between protein drugs and low molecular weight drugs.
  • ANDERSSON L, BLOMBERG L, FLEGEL M, LEPSA L, NILSSON B, VERLANDER M: Large-scale synthesis of peptides. Biopolymers (2000) 55:227–250.
  • •Excellent review on the synthesis of peptides.
  • SCHMIDT FR: Recombinant expression systems in the pharmaceutical industry. Appl Microbial. Biotechnol (2004) 65:363–372.
  • •A brief but excellent review of the most common expression systems used today.
  • WALSH G: Therapeutic insulins and their large-scale manufacture. Appl. Microbial. Biotechnol (2005) 67:151–159.
  • WURM FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotech. (2004) 22:1393–1398.
  • ROY N, AGARWAL S: Therapeutic protein production - an overview. Business Briefing: Future Drug Discovery (2003):79–82.
  • WERNER RG: Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol (2004) 113:171–182.
  • ROQUE AC, LOWE CR, TAIPA MA: Antibodies and genetically engineered related molecules: production and purification. Biotechnol Frog. (2004) 20:639–654.
  • DESAI MA: Downstream Processing of Proteins. MA Desai (Ed.), Humana Press, Totowa, NJ, USA (2000).
  • ••This book gives detailed descriptionsof all aspects of downstream processing, and is recommended to anyone working in the field.
  • CLELAND JL, DAUGHERTY A, MRSNY R: Emerging protein delivery methods. Curt Opin. Biotechnol (2001) 12:212–219.
  • HOLLANDER PA, BLONDE L, ROWER et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes. Diabetes Care (2004) 27:2356–2362.
  • MANDAL TK: Inhaled insulin for diabetesmellitus. Am. Health Syst. Pharm. (2005) 62:1359–1364.
  • CEFALU WT: Evolving strategies for insulin delivery and therapy. Drugs (2004) 64:1149–1161.
  • •The experience with insulin, well described in this review, may serve as inspiration for other protein pharmaceuticals.
  • CRYAN S-A: Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. (2005) 7:E20–E41.
  • LEVIN G, GERSHONOWITZ A, SACKS H et al.: Transdermal delivery of human growth hormone through RF-microchannels. Pharm. Res. (2005) 22:550–555.
  • KALIA YN, NAIK A, GARRISON J, GUY RH: Iontophoretic drug delivery. Adv. Drug Deify. Rev (2004) 56:619–658.
  • MITRAGOTRI S, BLANKSCHTEIN D, LANGER R: Ultrasound-mediated transdermal protein delivery. Science (2005) 269:850–853.
  • CEVC G, GEBAUER D, STIEBER J, SCHÄTZLEIN A, BLUME G: Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta (1998) 1368:201–215.
  • PRAUSNITZ MR: Microneedles for transdermal drug delivery. Adv. Drug Deity Rev (2004) 56:581–587.
  • TORKER S, ONUR E, OZER Y: Nasal route and drug delivery systems. Pharm. World Sci. (2004) 26:137–142.
  • LEARY AC, STOTE RM, BREEDT HJ, O'BRIEN J, BUCKLEY B: Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes 7echnol. Ther. (2005) 7:124–130.
  • REGER MA, WATSON GS, FREY WH 2nd et al: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging (2005) (In press).
  • ROSS TM, MARTINEZ PM, RENNER JC, THORNE RG, HANSON LR, FREY WH 2nd: Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. Neuroimmunol (2004) 151:66–77.
  • KIPNES M, DANDONA P, TRIPATHY D, STILL JG, KOSUTIC G: Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with Type 2 diabetes. Diabetes Care (2003) 26:421–426.
  • GUEVARA-AGUIRRE J, GUEVARA M,SAAVEDRA J, MIHIC M, MODI P: Oral spray insulin in treatment of Type 2 diabetes: a comparison of efficacy of the oral spray insulin (oralin) with subcutaneous (SC) insulin injection: a proof of concept study. Diabetes Metab. Res. Rev (2004) 20:472–478.
  • KRONES A, KIETZMANN T, JUNGERMANN K: Perivenous localization of insulin receptor protein in rat liver, and regulation of its expression by glucose and oxygen in hepatocyte cultures. Biochem. J. (2000) 348:433–438.
  • TANG L, PERSKY AM, HOCHHAUS G, MEIBOHM B: Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. (2004) 93:2184–2204.
  • FOSTER N, HIRST BH: Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deity. Rev (2005) 57:431–450.
  • BOHANNON NJ: Insulin delivery using pen devices. Simple to use tools may help young and old alike. Postgrad. Med. (1999) 106:57–68.
  • ARAKAWA T, PRESTRELSKI SJ, KENNEY WC, CARPENTER JF: Factors affecting short-term and long-term stability of proteins. Adv. Drug Deily. Rev (2001) 46:307–326.
  • FROKJAER S, OTZEN DE: Protein drugstability: a formulation challenge. Nat. Drug Discov. (2005) 4:298–306.
  • •This review describes the intricate relationship between protein stability and formulation.
  • KRISHNAMURTHY R, MANNING MC: The stability factor: importance in formulation development. Curr. Pharm. Biotechnol (2002) 3:361–371.
  • FAGAIN C: Understanding and increasing protein stability. Biochim. Biophys. Acta (1995) 1252:1–14.
  • WANG W: Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. (1999) 185:129–188.
  • •A compilation of almost all published protein formulation research in the literature up to 1999.
  • REUBSAET JL, BEIJNEN JH, BULT A, VAN MAANEN RJ, MARCHAL JA, UNDERBERG WJ: Analytical techniques used to study the degradation of proteins and peptides: chemical instability. J. Pharm. Biomed. Anal (1998) 17:955–978.
  • REUBSAET JL, BEIJNEN JH, BULT A, VAN MAANEN RJ, MARCHAL JA, UNDERBERG WJ: Analytical techniques used to study the degradation of proteins and peptides: physical instability. Pharm. Biomed. Anal. (1998) 17:979–984.
  • JISKOOT W, CROMMELIN DJ: Methods for Structural Analysis of Protein Pharmaceuticals.W DJ Crommelin (Eds), AAPS Press, Arlington, VA, USA (2005).
  • ••An excellent compilation of almost allanalytical techniques used to characterise proteins in formulations.
  • NIELSEN L, FROKJAER S, BRANGE J, UVERSKY VN, FINK AL: Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry (2001) 40:8397–8409.
  • DEPAZ RA, BARNETT CC, DALE DA, CARPENTER JF, GAERTNER AL, RANDOLPH TW: The excluding effects of sucrose on a protein chemical degradation pathway: methionine oxidation in subtilisin. Arch. Biochem. Biophys. (2000) 384:123–132.
  • SOENDERKAER S, CARPENTER JF, VAN WEERT M, HANSEN LL, FLINK J, FROKJAER S: Effects of sucrose on rFVIIa aggregation and methionine oxidation. Eur. Pharm. Sci. (2004) 21:597–606.
  • CARPENTER JF, MANNING MC: Rational Design of Stable Protein Formulations - Theory and Practice. JF C MC Manning (Eds), Kluwer Academic/Plenum Publishers, New York, NY, USA (2002).
  • •Gives a good insight into the rational design of protein formulations.
  • WANG W: Lyophilization and development of solid protein pharmaceuticals. Int. Pharm. (2000) 203:1–60.
  • COSTANTINO HR, PIKAL MJ: Lyophilization of Biopharmaceuticals. HR C MJ Pikal (Eds), AAPS Press, Arlington, VA, USA (2005).
  • CARPENTER JF, PRESTRELSKI SJ, DONG A: Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur. Pharm. Biopharm. (1998) 45:231–238.
  • CHANG BS, BEAUVAIS RM, DONG A, CARPENTER JF: Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation. Arch. Biochem. Biophys. (1996) 331:249–258.
  • COSTANTINO HR, CARRASQUILLO KG, CORDERO RA, MUMENTHALER M, HSU CC, GRIEBENOW K: Effects of excipients on the stability and structure of lyophilized recombinant human growth hormone. Pharm. Sci. (1998) 87:1412–1420.
  • DEPAZ RA, DALE DA, BARNETT CC, CARPENTER JF, GAERTNER AL, RANDOLPH TW: Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: role of protein conformation and molecular mobility. Enzyme Microb. 7echnol. (2002) 31:765–774.
  • PASSOT S, FONSECA F, ALARCON-LORCA M, ROLLAND D, MARIN M: Physical characterisation of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage. Eur. I Pharm. Biopharm. (2005) 60:335–348.
  • REMMELE RL, STUSHNOFF C, CARPENTER JF: Real-time in situ monitoring of lysozyme during lyophilization using infrared spectroscopy: dehydration stress in the presence of sucrose. Pharm. Res. (1997) 14:1548–1555.
  • WEBB SD, GOLLEDGE SL, CLELAND JL, CARPENTER JF, RANDOLPH TW: Surface adsorption of recombinant human interferon-y in lyophilized and spray-lyophilized formulations. J. Pharm. Sci. (2002) 91:1474–1487.
  • TANG X, PIKAL MJ: Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm. Res. (2004) 21:191–200.
  • MAA Y- PRESTRELSKI SJ: Biopharmaceutical powders: particle formation and formulation considerations. Curr. Pharm. Biotechnol (2000) 1:283–302.
  • JOVANOVIC N, BOUCHARD A, HOFLAND GW, WITKAMP G- CROMMELIN DJ, JISKOOT W: Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res. (2004) 21:1955–1969.
  • OKAMOTO H, TODO H, IIDA K, DANJO K: Dry powders for pulmonary delivery of peptides and proteins. KONA (2002) 20:71–83.
  • SONNER C, MAA Y- LEE G: Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability. Pharm. Sci. (2002) 91:2122–2139.
  • YU Z, GARCIA AS, JOHNSTON KP, WILLIAMS RO 3rd: Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles. Eur. Pharm. Biopharm. (2004) 58:529–537.
  • CLELAND JL, DUENAS ET, PARK A et al.: Development of poly- (D,t-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control. Release (2001) 72:13–24.
  • HANSEN TK: Pharmacokinetics and acute lipolytic actions of growth hormone - impact of age, body composition, binding proteins, and other hormones. Growth Horm. IGF Res. (2002) 12:342–358.
  • HAVELUND S, PLUM A, RIBEL U et al: The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. (2004) 21:1498–1504.
  • PASUT G, GUIOTTO A, VERONESE FM: Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opin. Ther. Patents (2004) 14:859–894.
  • ••A very extensive review on almost allaspects of drug pegylation, Including proteins.
  • CALICETI P: Pharmacokinetics of pegylated interferons: what is misleading? Dig. Liver Dis. (2004) 36\(Suppl. 3):S334–S339.
  • DRIVE G, GASCON AR, HERNANDEZ RM, DOMINGUEZ-GIL A, PEDRAZ JL: Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol. Li. (2004) 25:382–387.
  • WEERT M, HENNINK WE, JISKOOT W: Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. (2000) 17:1159–1167.
  • BILATI U, ALLEMAN E, DOELKER E: Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. Pharm. Biopharm. (2005) 59:375–388.
  • TRACY MA: Development and scale-up of a microsphere protein delivery system. Biotechnol Frog. (1998) 14:108–115.
  • •A rare insight into the industrial production of an advanced delivery system.
  • CLELAND JL, JOHNSON OL, PUTNEY S, JONES AJ: Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Deify. Rev (1997) 28:71–84.
  • SCHELLEKENS H: Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. (2002) 24:1720–1740.
  • ••Describes the important aspects of proteinimmunogenicity and its potential causes.
  • CHAMBERLAIN P, MIRE-SLUIS AR: An overview of scientific and regulatory issues for the immunogenicity of biological products. Dev. Biol. Basel (2003) 112:3–11.
  • FROST H: Antibody-mediated side-effects of recombinant proteins. Toxica (2005) 209:155–160.
  • HERMELING S, CROMMELIN DJ, SCHELLEKENS H, JISKOOT W: Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. (2004) 21:897–903.
  • SCHELLEKENS H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev (2002) 1:457–462.
  • CASADEVALL N, ROSSERT J: Importance of biologic follow-ons: experience with EPO. Best Pract. Res. Haematol (2005) 18:381–387.
  • EVENS AM, BENNETT CL, LUMINARI S: Epoetin-indcued pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract. Res. Hannatol (2005) 18:481–489.
  • SCHELLEKENS H: Immunological mechanisms of EPO-associated pure red cell aplasia. Best Pract. Res. Clin. Hannatol (2005) 18:473–480.
  • BOVEN K, STRYKER S, KNIGHT J et al: The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney mt. (2005) 67:2346–2353.
  • HERMELING S, SCHELLEKENS H, CROMMELIN DJ, JISKOOT W: Micelle-associated protein in epoietin formulations: a risk factor for immunogenicity. Pharm. Res. (2003) 20:1903–1907.
  • HERMELING S, JISKOOT W, CROMMELIN DJ, BORNiES C, SCHELLEKENS H: Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. (2005) 22:847–851.
  • MIRE-SLUIS AR, BARRETT YC, DEVANARAYAN V et al: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol Methods (2004) 289:1–16.
  • GENG D, SHANKAR G, SCHANTZ A, RAJADHYAKSHA M, DAVIS H, WAGNER C: Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. Pharm. Biomed. Anal. (2005) 39:364–375.
  • DOVE A: Betting on biogenerics. Nat. Biotech. (2001) 19:117–120.
  • CHAMBERLAIN P: Biogenerics: Europe takes another step forward while the FDA dives for cover. Drug Discov. Today (2004) 9:817–820.

Website

  • http://www.phrma.org/newmedicines/ biotech/HOLMER AF: 324 biotechnology medicines in testing promise to bolster the arsenal against disease (2004).
  • http://wwwjnjpharmarnd.com/company/ n-casereports.html Johnson & Johnson Pharmaceutical Research & Development update regarding erythropoietin antibody-positive pure red cell aplasia (July 2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.